Von Willebrand factor

Latest Updates of Viva Biotech's Portfolio Companies

Retrieved on: 
Wednesday, March 6, 2024
Fabry disease, RMB, PD, Drug development, Strong, Ohio State University, RNA, Insight Partners, Pharmacology, American College, Radiopharmaceutical, VBI, Willebrand, RTW, Pattern hair loss, GMP, Stroke, Good manufacturing practice, Therapy, Skin, GCS, Atopic dermatitis, Safety, Pharmacokinetics, Von Willebrand factor, Investment, AstraZeneca, Innovation, Groundbreaking, Patient, ARCH Venture Partners, Pharmaceutical industry

NEWARK, Calif.-- AceLink Therapeutics, Inc., invested and incubated by Viva BioInnovator (VBI), is a clinical-stage biopharmaceutical company developing next generation oral substrate reduction therapies (SRTs). Recently they announced that the findings from their Phase 1 study of AL01211 in healthy volunteers have been published in the peer-reviewed journal Clinical Pharmacology in Drug Development, a journal of the American College of Clinical Pharmacy. AL01211 is a potent, oral, glucosylceramide synthase (GCS) inhibitor being developed for the treatment of Fabry disease and Type 1 Gaucher disease.

Key Points: 
  • This continuous innovation keeps companies up to date and promotes the evolution of R&D and the success of commercialization.
  • Recently, Viva Biotech's portfolio companies have new updates.
  • NEWARK, Calif.-- AceLink Therapeutics, Inc., invested and incubated by Viva BioInnovator (VBI), is a clinical-stage biopharmaceutical company developing next generation oral substrate reduction therapies (SRTs).
  • Previously, the company had completed a $5.4 million seed funding round, with investors including Rev1 Ventures, Broadview Ventures, and Viva Biotech.

Basking Biosciences Announces Close of $55 Million Financing to Accelerate Clinical Development for First Reversible Thrombolytic for Ischemic Stroke

Retrieved on: 
Thursday, February 1, 2024
Cardiology, Biotechnology, Managed Care, Other Health, Health, Pharmaceutical, Other Science, Research, Hospitals, Science, Clinical Trials, Willebrand, RTW, ARCH Venture Partners, RNA, Joseph, Thrombosis, University, Translational research, Patient, Safety, Foothills Medical Centre, AIS, Insight Partners, Ohio State University, Investment, Radiology, Stroke, Surgery, Medicine, Von Willebrand factor, Pharmaceutical industry

Basking Biosciences (Basking), a clinical-stage biopharmaceutical company developing a novel acute thrombolytic therapy to treat stroke, today announced the close of a $55 million financing.

Key Points: 
  • Basking Biosciences (Basking), a clinical-stage biopharmaceutical company developing a novel acute thrombolytic therapy to treat stroke, today announced the close of a $55 million financing.
  • Steven Gillis, Ph.D., Managing Director of ARCH Venture Partners will serve as Chairman of Basking’s Board of Directors .
  • Basking will utilize the proceeds to accelerate clinical development of BB-031, a first-in-class, reversible RNA aptamer targeting von Willebrand Factor (vWF), engineered for rapid onset and short duration of effect.
  • Basking will initiate a Phase 2 proof-of-concept trial, the RAISE trial, in patients with acute ischemic stroke (AIS) in 2024.

Human medicines European public assessment report (EPAR): Veyvondi, vonicog alfa, Date of authorisation: 31/08/2018, Revision: 9, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Patient, Medical Subject Headings, Marketing, Agency, INN, Allergy, ATC, Antibody, Plasma, Blood, DDAVP, International, Bleeding, Von Willebrand factor, Injection, Headache, Disease, Coagulopathy, Language, Hypersensitivity, European Medicines Agency, Von Willebrand disease, Select, Anatomy, IIA, VWD, Medical device

Human medicines European public assessment report (EPAR): Veyvondi, vonicog alfa, Date of authorisation: 31/08/2018, Revision: 9, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Veyvondi, vonicog alfa, Date of authorisation: 31/08/2018, Revision: 9, Status: Authorised

Bloodbuy Announces Agreement with Cerus Corporation to Offer Pathogen Reduced Cryoprecipitated Fibrinogen Complex on its Digital Marketplace

Retrieved on: 
Wednesday, November 1, 2023
Data Management, Practice Management, Technology, Managed Care, Other Health, Health, Health Technology, Software, Hospitals, Networks, Mobile, Wireless, XIII, CERS, Von Willebrand factor, Cerus Corporation, Factor XIII, Organization, Factor, Hemostasis, Multimedia, Hospital, Blood, Bleeding, Friction, Patient, China Biologic Products, Pharmaceutical industry

Bloodbuy, a healthcare software and services company focused on developing cloud-based technologies that transform how biological products are managed and disseminated, today announced that it has entered into an agreement with Cerus Corporation (NASDAQ: CERS) to offer Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT® Fibrinogen Complex, or “IFC”) via the Bloodbuy online marketplace.

Key Points: 
  • Bloodbuy, a healthcare software and services company focused on developing cloud-based technologies that transform how biological products are managed and disseminated, today announced that it has entered into an agreement with Cerus Corporation (NASDAQ: CERS) to offer Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT® Fibrinogen Complex, or “IFC”) via the Bloodbuy online marketplace.
  • Bloodbuy’s flagship cloud-based platform connects hospitals, blood centers, and life sciences organizations using its multi-patented B2B e-commerce and computer networking technologies for blood and biological products.
  • View the full release here: https://www.businesswire.com/news/home/20231101749546/en/
    Bloodbuy Announces Agreement with Cerus Corporation to Offer Pathogen Reduced Cryoprecipitated Fibrinogen Complex on its Digital Marketplace (Photo: Business Wire)
    IFC is a pathogen reduced blood component for fibrinogen supplementation with a 5-day post-thaw shelf life.
  • Bloodbuy enables blood centers and hospitals, via its unique online marketplace, to redistribute available blood products quickly and easily across its vast network, taking the friction out of this mission critical activity.

Precision BioLogic's Factor VIII Deficient Plasma with VWF Now FDA-Cleared for Sale in U.S.

Retrieved on: 
Monday, September 18, 2023
Factor VIII, Haemophilia, Research, Biologic, ISTH, Von Willebrand factor, Plasma, VWF, Traction, Hemostasis, VIII, FDA, Vaccine, EU, NS

The latest in Precision BioLogic's family of factor deficient plasmas, CRYOcheck Factor VIII Deficient Plasma with VWF is intended for use in clinical laboratories to identify factor VIII (FVIII) deficiency in human plasma and aid in the management of hemophilia A.

Key Points: 
  • The latest in Precision BioLogic's family of factor deficient plasmas, CRYOcheck Factor VIII Deficient Plasma with VWF is intended for use in clinical laboratories to identify factor VIII (FVIII) deficiency in human plasma and aid in the management of hemophilia A.
  • CRYOcheck Factor VIII Deficient Plasma with VWF comes in a convenient frozen format, which eliminates reconstitution errors and reduces preparation time.
  • CRYOcheck Factor VIII Deficient Plasma with VWF launched in Canada, the EU, UK, Australia and New Zealand in 2021.
  • "CRYOcheck Factor VIII Deficient Plasma with VWF offers labs a readily available and reliable alternative to congenital FVIII deficient plasmas.

Global Von Willebrand Disease (VWD) Treatment Market Report 2023: Increasing Public Awareness Related to VWD Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, June 12, 2023
Biotechnology, Pharmaceutical, Health, Bleeding, VWD, Eagle, DDAVP, Type, Government, Lymphocytosis, Von Willebrand factor, VWF, Von Willebrand disease, Patient, Fibrin, Blood, Growth, Diagnosis, Rare, Research, FDA, Hormone replacement therapy, Pharmaceutical industry, Teva

On the basis of type of VWD, von Willebrand disease treatment market can be segmented as Type 1 VWD, Type 2 VWD and Type 3 VWD.

Key Points: 
  • On the basis of type of VWD, von Willebrand disease treatment market can be segmented as Type 1 VWD, Type 2 VWD and Type 3 VWD.
  • The types of therapeutic treatments used against von Willebrand disease are Desmopressin (DDAVP), hormone replacement therapy, contraceptives, anti-fibrinolytic or clot-stabilizing drugs, and fibrin sealants.
  • The key factor responsible for growth of von Willebrand disease is increasing public awareness related to VWD which is fueling the diagnosis rate in North America and Europe.
  • North America was observed as the largest market for von Willebrand disease treatment followed by Europe.

Basking Biosciences Presents Novel Reversible RNA-aptamer Thrombolytic at Locus Walk RNA Innovation Conference

Retrieved on: 
Tuesday, May 9, 2023
Science, Neurology, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Partnership, University of Massachusetts, Bleeding, Stroke, Toxicity, Brain, RNA, Willebrand, Von Willebrand factor, Blood, MRI, Patient, Thrombus, Beth Israel, Aptamer, Conference, Vaccine

Basking Biosciences (Basking), a clinical-stage biopharmaceutical company, today discussed the development status of BB-031, the company’s novel, RNA-based thrombolytic for use in patients experiencing acute ischemic stroke, at the Locus Walk RNA Innovation Conference, held virtually.

Key Points: 
  • Basking Biosciences (Basking), a clinical-stage biopharmaceutical company, today discussed the development status of BB-031, the company’s novel, RNA-based thrombolytic for use in patients experiencing acute ischemic stroke, at the Locus Walk RNA Innovation Conference, held virtually.
  • BB-031, a rapid onset, short-acting agent, is an RNA aptamer targeting von Willebrand Factor (vWF), a key structural component of thrombi and driver of blood clotting.
  • Uniquely, the thrombolytic activity of BB-031 is designed to be quickly neutralized in the event of bleeding using a complementary agent, BB-025, which Basking is developing in tandem.
  • “RNA aptamers have a number of characteristics that make them exceptionally well suited for treating acute thrombosis,” said Richard Shea, Chief Executive Officer of Basking.

Positive topline results from pivotal XTEND-Kids phase 3 study of efanesoctocog alfa in children under 12 years of age with haemophilia A: Swedish Orphan Biovitrum AB

Retrieved on: 
Thursday, March 2, 2023
Research and development, Doctor of Philosophy, Safety, Haemophilia, Factor VIII, Patient, Genetic disorder, Bleeding, Pain, Standard of care, MD, ABR, Civil service commission, Von Willebrand factor, Medicine, Pharmacokinetics, Development, Male, Swedish Orphan Biovitrum, Medical Affairs Bureau, European Commission, VIII, Pharmaceutical industry, Medical device, Sanofi, EU

No factor VIII inhibitors were observed in the 74 children enrolled in the study, of which 65 experienced at least 50 exposure days.

Key Points: 
  • No factor VIII inhibitors were observed in the 74 children enrolled in the study, of which 65 experienced at least 50 exposure days.
  • Haemophilia A is a rare, genetic disorder in which the ability of a person's blood to clot is impaired due to a lack of factor VIII.
  • Combined with the XTEND-1 phase 3 trial, these results will provide the basis for regulatory submission in the EU.
  • Efanesoctocog alfa was granted orphan designation by the European Commission in June 2019 and the medicine was recently approved in the US .

Positive topline results from pivotal XTEND-Kids phase 3 study of efanesoctocog alfa in children under 12 years of age with haemophilia A: Swedish Orphan Biovitrum AB

Retrieved on: 
Thursday, March 2, 2023
Research and development, Doctor of Philosophy, Safety, Haemophilia, Factor VIII, Patient, Genetic disorder, Bleeding, Pain, Standard of care, MD, ABR, Civil service commission, Von Willebrand factor, Medicine, Pharmacokinetics, Development, Male, Swedish Orphan Biovitrum, Medical Affairs Bureau, European Commission, VIII, Pharmaceutical industry, Medical device, Sanofi, EU

No factor VIII inhibitors were observed in the 74 children enrolled in the study, of which 65 experienced at least 50 exposure days.

Key Points: 
  • No factor VIII inhibitors were observed in the 74 children enrolled in the study, of which 65 experienced at least 50 exposure days.
  • Haemophilia A is a rare, genetic disorder in which the ability of a person's blood to clot is impaired due to a lack of factor VIII.
  • Combined with the XTEND-1 phase 3 trial, these results will provide the basis for regulatory submission in the EU.
  • Efanesoctocog alfa was granted orphan designation by the European Commission in June 2019 and the medicine was recently approved in the US .

Basking Biosciences to Present Clinical Trial Results on First Reversible Thrombolytic Agent at American Heart Association International Stroke Conference 2023

Retrieved on: 
Tuesday, January 31, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Cardiology, American Heart, Von Willebrand factor, Blood, RNA, University, Drug-induced QT prolongation, ISC, Safety, University of Pittsburgh, Bleeding, Conference, Thrombolysis, Doctor of Philosophy, Pharmaceutical industry, Stroke, Pharmacokinetics, Tolerability

Basking Biosciences, a clinical-stage biopharmaceutical company developing the first reversible thrombolytic therapeutic for ischemic stroke, today announced the company will be presenting three oral presentations and two moderated posters concerning the company’s novel drug candidate at the American Heart Association’s 2023 International Stroke Conference (ISC).

Key Points: 
  • Basking Biosciences, a clinical-stage biopharmaceutical company developing the first reversible thrombolytic therapeutic for ischemic stroke, today announced the company will be presenting three oral presentations and two moderated posters concerning the company’s novel drug candidate at the American Heart Association’s 2023 International Stroke Conference (ISC).
  • The ISC is being held both live and virtually from February 8-10 in Dallas, Texas.
  • “Current drug treatments for acute ischemic stroke have been restricted by a narrow therapeutic window and high risk of bleeding.
  • It is a rapid-onset, short-acting thrombolytic agent that is capable of recanalizing blocked blood vessels within a greatly extended therapeutic window than current therapy.”